Signals, Powered By EquityPandit
Glenmark Pharmaceuticals Inc. USA has been given final approval by the United States Food & Drug Administration (USFDA), for Clobetasol Propionate Spray, 0.05%, the generic version of Clobex Spray, 0.05%, of Galderma Laboratories, L.P.
The product will be manufactured at the company’s Baddi manufacturing plant in Hyderabad, India. The product which has received approval is used for treatment of moderate to severe plaque psoriasis in India.
Furthermore, Glenmark’s current portfolio consists of 131 products which are authorized for distribution in the US marketplace and 63 ANDA’s are pending for approval with the USFDA.
